We first analyzed the potential of R-3 in reversing doxorubicin resistance in human cancer cell lines of different origin (i.e., colon, lung, and breast cancer), characterized by sensitivity or acquired resistance to the drug [29]. This evidence concerns the gene CD1D and breast carcinoma.